Quipt Home Medical (QIPT) Q3 2024 earnings summary

Executive summary

• Q2 2024 revenue was $64 million, up 10% year-over-year, with a 23.3% adjusted EBITDA margin and 14% adjusted EBITDA growth; Q3 2024 revenue was $64.0 million, up 6.1% year-over-year, with a 22.3% margin and 2.7% adjusted EBITDA growth.

• Organic growth contributed $6.4 million or 6.5% year-over-year in Q2 and $8.1 million (5%) for the nine months ended June 30, 2024.

• Recurring revenue represented 80% of Q2 and 82% of Q3 revenue, driven by growth in new equipment set-ups.

• The company faced headwinds from the end of Medicare 75/25 relief, Medicare Advantage member withdrawals, and the Change Healthcare cyberattack impacting claims and cash flow.

• Operational highlights include serving 270,087 unique patients in the nine months ended June 30, 2024, up 12.9% year-over-year.

Financial highlights

• Nine-month revenue reached $193.3 million, up 21.4% year-over-year; Q2 revenue was $64 million (up 10%), and six-month revenue was $129.3 million (up 31%).

• Adjusted EBITDA for the nine months was $44.5 million (23.0% margin), with Q2 at $14.9 million (23.3% margin) and Q3 at $14.2 million (22.3% margin).

• Free cash flow for Q2 was $5.9 million (9% of revenue); cash flow from operations for the nine months was $28.6 million.

• CapEx for six months was $7.1 million (11.2% of revenue), down from $7.9 million year-over-year.

• Bad debt expense rose to 5.0% of revenue in Q3 2024, up from 4.0% in Q3 2023, mainly due to the cyber incident.

Outlook and guidance

• Revenue for Q2 is considered a baseline for the remainder of fiscal 2024, with expectations of returning to historic 2% sequential quarter-over-quarter growth.

• Management expects consistent adjusted EBITDA margin performance and a return to historical organic growth levels.

• Free cash flow is expected at 6%-8% of revenue after CapEx and lease payments, before debt service and acquisitions.

• Focus remains on disciplined capital management, organic growth, and identifying synergistic acquisition opportunities.